Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
Superior Efficacy of Denosumab Over Zoledronic Acid in Increasing Femoral Neck Bone Mineral Density in Osteoporosis Patients With Type 2 Diabetes Mellitus.
СтатьяКлиническое исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Han Dongxu, Li Bingxin, Liu Jingnan, Chen Liqin, Wang Hongxia, Yuan Lingdan, Xuan Miao, Song Lige
Аннотация
OBJECTIVES: This study aimed to compare the antiosteoporotic efficacy of zoledronic acid (ZOL) with denosumab (DEN) in osteoporosis patients with type 2 diabetes mellitus (T2DM).
METHODS: This was a prospective, open-label, nonrandomized clinical study. Osteoporotic women with T2DM aged 50 to 80 years were enrolled and assigned to either the ZOL group (n = 45) or the DEN group (n = 75) based on patient preference. The efficacy endpoint included the percent change from baseline in bone mineral density (BMD), bone turnover markers, and the fracture risk evaluated by the fracture risk assessment tool after 1 year. The propensity score-matched analysis was performed to confirm the robustness.
RESULTS: After 1-year of treatment, DEN was more effective than ZOL at increasing femoral neck BMD (least-squares mean [LS mean] difference 4.59% [95% confidence interval [CI]: 0.93% to 8.25%]; P = .017), but not at BMD in the lumbar spine or total hip. Besides, compared with the ZOL group, the DEN group demonstrated greater suppression of osteocalcin (LS mean difference -20.58% [95% CI: -39.93 to -1.24]; P = .041) and a greater reduction in major osteoporotic fracture risk (LS mean difference -11.20% [95% CI: -20.76 to -1.64]; P = .025).
CONCLUSIONS: The results suggest that DEN should be considered as a potentially better option for T2DM patients who have low femoral neck BMD.
METHODS: This was a prospective, open-label, nonrandomized clinical study. Osteoporotic women with T2DM aged 50 to 80 years were enrolled and assigned to either the ZOL group (n = 45) or the DEN group (n = 75) based on patient preference. The efficacy endpoint included the percent change from baseline in bone mineral density (BMD), bone turnover markers, and the fracture risk evaluated by the fracture risk assessment tool after 1 year. The propensity score-matched analysis was performed to confirm the robustness.
RESULTS: After 1-year of treatment, DEN was more effective than ZOL at increasing femoral neck BMD (least-squares mean [LS mean] difference 4.59% [95% confidence interval [CI]: 0.93% to 8.25%]; P = .017), but not at BMD in the lumbar spine or total hip. Besides, compared with the ZOL group, the DEN group demonstrated greater suppression of osteocalcin (LS mean difference -20.58% [95% CI: -39.93 to -1.24]; P = .041) and a greater reduction in major osteoporotic fracture risk (LS mean difference -11.20% [95% CI: -20.76 to -1.64]; P = .025).
CONCLUSIONS: The results suggest that DEN should be considered as a potentially better option for T2DM patients who have low femoral neck BMD.